Stock ABS ARTERRA BIOSCIENCE S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Arterra Bioscience S.p.A.

Equities

ABS

IT0005386369

Biotechnology & Medical Research

Market Closed - Borsa Italiana
Other stock markets
 16:44:59 10/05/2024 BST 		5-day change 1st Jan Change
1.97 EUR -1.50% Intraday chart for Arterra Bioscience S.p.A. -1.50% +18.67%
05-08 Mib bearish; focus on quarterlies AN
05-07 Mib still in the green; Campari drags bullishness AN

Valuation

Fiscal Period: December 2019 2020 2021 2022
Capitalization 1 24.8 18.74 19.07 14.38
Enterprise Value (EV) 1 21.14 15.01 14.87 8.88
P/E ratio 28.9 x - - -
Yield - - 1.72% 4.63%
Capitalization / Revenue 9.04 x 4.49 x 4.02 x 2.99 x
EV / Revenue 7.7 x 3.6 x 3.14 x 1.85 x
EV / EBITDA 44.7 x 9.37 x 8.57 x 4.16 x
EV / FCF -43,606,596 x -22,773,227 x -182,950,728 x 6,996,957 x
FCF Yield -0% -0% -0% 0%
Price to Book 3.49 x - - -
Nbr of stocks (in thousands) 6,545 6,575 6,575 6,658
Reference price 2 3.790 2.850 2.900 2.160
Announcement Date 10/04/20 07/06/21 13/04/22 14/04/23
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 2.062 2.451 2.745 4.173 4.742 4.805
EBITDA 1 0.5393 0.608 0.4729 1.602 1.735 2.133
EBIT 1 0.3962 0.5346 0.1766 1.201 1.248 1.601
Operating Margin 19.22% 21.81% 6.43% 28.79% 26.32% 33.31%
Earnings before Tax (EBT) 1 1.017 1.073 0.9405 1.199 1.274 1.797
Net income 1 0.7453 1.044 0.8572 1.109 1.111 1.414
Net margin 36.15% 42.59% 31.23% 26.57% 23.42% 29.43%
EPS - 0.2085 0.1310 - - -
Free Cash Flow - -0.3489 -0.4847 -0.6592 -0.0813 1.269
FCF margin - -14.23% -17.66% -15.8% -1.71% 26.41%
FCF Conversion (EBITDA) - - - - - 59.51%
FCF Conversion (Net income) - - - - - 89.76%
Dividend per Share - - - - 0.0500 0.1000
Announcement Date 24/10/19 24/10/19 10/04/20 07/06/21 13/04/22 14/04/23
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 0.38 0.16 - - - -
Net Cash position 1 - - 3.67 3.73 4.2 5.5
Leverage (Debt/EBITDA) 0.7076 x 0.2551 x - - - -
Free Cash Flow - -0.35 -0.48 -0.66 -0.08 1.27
ROE (net income / shareholders' equity) - 48.8% 17.7% 14.5% 12.6% 14.2%
ROA (Net income/ Total Assets) - 8.1% 1.54% 7.55% 7.12% 8.28%
Assets 1 - 12.89 55.66 14.67 15.59 17.07
Book Value Per Share - 0.5100 1.090 - - -
Cash Flow per Share - 0.1500 0.7100 - - -
Capex 1 0.05 0.45 0.84 0.34 0.54 0.09
Capex / Sales 2.63% 18.23% 30.76% 8.2% 11.41% 1.96%
Announcement Date 24/10/19 24/10/19 10/04/20 07/06/21 13/04/22 14/04/23
1EUR in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARTERRA BIOSCIENCE S.P.A. Stock Arterra Bioscience S.p.A.
+18.67% 14.13M
MODERNA, INC. Stock Moderna, Inc.
+17.96% 44.96B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.17% 42.65B
LONZA GROUP AG Stock Lonza Group AG
+48.77% 41.85B
CELLTRION, INC. Stock Celltrion, Inc.
-4.27% 29.04B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.42% 26.08B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.39% 19.03B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.86% 12.75B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.29% 12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.50% 11.75B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ABS Stock
  4. Financials Arterra Bioscience S.p.A.